Quince Therapeutics announced top-line results from its pivotal Neat Phase III trial evaluating dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) in ataxia‑telangiectasia (A‑T). The study failed to meet its primary and key secondary endpoints, and the company is abandoning the program. Investors reacted sharply: the stock collapsed, wiping out the asset’s core value and forcing the company to reassess its pipeline and cash runway. The failure underscores the high clinical and commercial risk in rare‑disease neurology development where single pivotal readouts determine company trajectories.